|

Interview With Henri Sant-Cassia

ByPsychedelic Spotlight

Similar Posts

  • Bad NEWS for NUMI, FieldTrip and J&J || Esketamine to Treat DEPRESSION Study Results And More

    Listen, Videos

    Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG esketamine study results, new 5MEO-DMT tests and Updates on the decriminalization efforts in California and Texas.

    In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

    1. We’ll cover some interesting and maybe disappoint results coming from a study designed to determine whether esketamine can treat depression and their implications on some companies such as Numinus Wellness (NUMI), Field Trip Health ( FTRP) and Johnsons & Johnson (JNJ)
    2. Study looking at the creativity benefits of taking psilocybin
    3. Compass Pathways (CMPS) has amazing new price targets
    4. First ever clinical trial testing the safety profile of a compound called 5MEO – DMT
    5. A couple of updates on decriminalization efforts

    Timestapms:

    0:00 – Intro
    1:33 – Likelihood of Adverse events from Nasal Esketamine : Implications for Numinus, JNJ and Fieldtrip Health
    6:07 – Psilocybin’s effects on creativity in a new placebo-controlled neuroimaging and it’s effects on MindMed (MMED/MMEDF), Compass Pathways (CMPS), Mydecine (MYCO) , Numinus ( NUMI)
    11:25 – Researchers to team up to produce the first ever 5-meo-DMT Psychedelic Training Program
    12:28 – California bill To Legalize Possession of Psychedelics Clears Second Senate Committee
    14:26 – Rick Perry supports the Texas Capital to study psychedelic drugs from PTSD in veterans.

    I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor

    If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifa
    ​…
    ​
    https://benzinga.grsm.io/thepsychedel

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #PsychedelicStocks ​#Numi #Mindmed

  • Interview with Sam Chapman, Executive Director of the Healing Advocacy Fund

    Listen, Podcasts

    This week on the Psychedelic Spotlight podcast, we talk with Sam Chapman. Sam is a resident of Portland, Oregon, he was the Campaign Manager for Oregon Measure 109, and is now the Executive Director of the Healing Advocacy Fund, a nonprofit organization dedicated to supporting the nation’s first regulated psilocybin therapy program.

  • MindMed ‘s Plan to END the Opioid Epidemic (How MMED / MMEDF Could Make Billions)

    Listen, Videos

    It is an unfortunate fact that the world is dealing with a second hidden epidemic: The Opioid Crisis. Luckily, MindMed ( MMED/ MMEDF ) has a solution: 18-MC. This Psychedelic Medicines company, which may soon be uplisted to the Nasdaq, is testing it’s ibogaine derivative to heal those effected by opioid addiction, whether from fentanyl or doctors’ prescriptions. We may have a light at the end of the tunnel, and the Opioid Epidemic may be defeated. This makes MindMed one of the best stocks for 2021. How much could this be worth? Tune in to find out!

    Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    Resources

    https://www.cdc.gov/nchs/pressroom/podcasts/20190911/20190911.htm

    https://www.ncbi.nlm.nih.gov/books/NBK541390/#:~:text=Morethan2millionpeople,diseasestraumaandsuicide.

    https://www.hhs.gov/opioids/about-the-epidemic/opioid-crisis-statistics/index.html#:~:text=In2018anestimated10.3,and808000peopleusedheroin.&text=Appropriateprescribingofopioidsis,andsafetyofMedicarebeneficiaries.

    https://www.ccsa.ca/opioids#:~:text=Canadaisinthemidst,publichealthandsafetyconcern.

    https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.17477

    https://www.publichealthontario.ca/-/media/documents/o/2020/opioid-mortality-covid-surveillance-report.pdf?la=en

    https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/opioid-addiction

    https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery

    https://preprod.drugfree.org/article/relapse-overdose/

    https://mindmed.co/psychedelic-inspired/#scroll_section-1

    https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine

    https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine

    https://s3.ca-central-1.amazonaws.com/ibosafe-pdf-resources/Ibogaine/Treating+drug+dependence+with+the+aid+of+ibogaine_a+retrospective+study.pdf

    https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine

    https://thethirdwave.co/psychedelics/ibogaine/

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382526/#:~:text=Theantiaddictiondrugibogainecertainlyaffectstheheartand,ibogaine’spotentiallylifethreateningcardiotoxicity.

    https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf

    https://www.ibogainealliance.org/18-mc/

    https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf

    #MindMed #MMED #MMEDF #MindMedNews #OpioidEpidemic #OpioidCrisis #MindMedStock #18MC #18-MC #PsychedelicStocks

  • Interview with Victoria and Joël, of Tandava Retreats

    Listen, Podcasts

    Swati sits down with leaders from Kaivalya Kollectiv, “a multifaceted company focusing on psychedelic wellness, education”, and more. She speaks with Victoria Wueshner, a 5-MeO-DMT Facilitator and the Founder of FIVE, and Joël Brierre, CEO of Kaivalya Kollectiv.